<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Targets and emerging therapies for schizophrenia</title>
  </titleInfo>
  <name type="personal">
    <namePart>Albert, Jeffrey S.</namePart>
  </name>
  <name type="personal">
    <namePart>Wood, Michael W. (Michael William)</namePart>
    <namePart type="date">1961-</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <genre authority="">Electronic books.</genre>
  <genre authority="local">Electronic books.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">nju</placeTerm>
    </place>
    <place>
      <placeTerm type="text">Hoboken, New Jersey</placeTerm>
    </place>
    <publisher>John Wiley &amp; Sons</publisher>
    <dateIssued>©2012</dateIssued>
    <dateIssued encoding="marc">2012</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="gmd">electronic resource</form>
    <extent>1 online resource.</extent>
  </physicalDescription>
  <tableOfContents>Dopaminergic hypothesis of schizophrenia : a historical perspective / Aurelija Jucaite and Svante Nyberg -- Dopamine D2/D3 partial agonists as antipsychotics / Philip G. Strange -- D1/D5 dopamine agonists as pharmacotherapy for schizophrenia / Kevin N. Boyd and Richard B. Mailman -- PDE inhibitors as a novel therapeutic approach for schizophrenia / Judith A. Siuciak and William J. Pitts -- Glutamatergic synaptic dysregulation in schizophrenia / Joseph T. Coyle, Alo Basu, and Michael Benneyworth -- Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia / Gerard J. Marek [and others] -- AMPA receptor positive modulators / John A. Morrow, John K.F. Maclean, and Craig Jamieson -- Progress in the exploration and development of GlyT1 inhibitors for schizophrenia / Jeffrey S. Albert and Michael W. Wood -- Combined dopamine D2 and 5-hydroxytryptamine (5-HT)1a receptor strategies for the treatment of schizophrenia, a pharmacological and chemical perspective / Andrew C. Mccreary, Roelof W. Feenstra, and Caitlin A. Jones -- 5-HT2C and 5-HT6 receptor targeted emerging approaches in schizophrenia / Sharon Rosenzweig-Lipson [and others] -- The cholinergic hypothesis : an introduction to the hypothesis and a short history / Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic -- Ŕ7 nicotinic acetylcholine receptors in the treatment of schizophrenia / Mihály Hajós, and Bruce N. Rogers -- Muscarinic acetylcholine receptors as novel targets for the development of therapeutics for schizophrenia / Christian C. Felder [and others] -- Will modulation of neuropeptide receptors produce the next generation of antipsychotic drugs? : a focus on the neurokinin and neurotensin systems / Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson -- GABA and schizophrenia / John H. Kehne and George D. Maynard.</tableOfContents>
  <note type="statement of responsibility">edited by Jeffrey S. Albert, Michael W. Wood.</note>
  <note>Includes bibliographical references and index.</note>
  <subject authority="lcsh">
    <topic>Schizophrenia</topic>
    <topic>Treatment</topic>
  </subject>
  <subject authority="mesh">
    <topic>Schizophrenia</topic>
    <topic>drug therapy</topic>
  </subject>
  <subject authority="bisacsh">
    <topic>PSYCHOLOGY</topic>
    <topic>Psychopathology</topic>
    <topic>Schizophrenia</topic>
  </subject>
  <subject authority="fast">
    <topic>Schizophrenia</topic>
    <topic>Treatment</topic>
  </subject>
  <classification authority="lcc">RC514</classification>
  <classification authority="ddc" edition="23">616.89/8061</classification>
  <classification authority="nlm">WM 203</classification>
  <relatedItem type="otherFormat" displayLabel="Print version:">
    <titleInfo>
      <title>Targets and emerging therapies for schizophrenia</title>
    </titleInfo>
    <originInfo>
      <publisher>Hoboken, N.J. : John Wiley &amp; Sons, ©2012</publisher>
    </originInfo>
    <identifier type="local">(DLC)  2011051091</identifier>
  </relatedItem>
  <identifier type="isbn">9781118309407</identifier>
  <identifier type="isbn">1118309405</identifier>
  <identifier type="isbn">9781118309384</identifier>
  <identifier type="isbn">1118309383</identifier>
  <identifier type="isbn">9781118309391</identifier>
  <identifier type="isbn">1118309391</identifier>
  <identifier type="isbn">9781118309421</identifier>
  <identifier type="isbn">1118309421</identifier>
  <identifier type="isbn">1280699310</identifier>
  <identifier type="isbn">9781280699313</identifier>
  <identifier type="isbn">0470322829</identifier>
  <identifier type="isbn">9780470322826</identifier>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="lccn">2011052987</identifier>
  <identifier type="stock number">10.1002/9781118309421 Wiley InterScience</identifier>
  <identifier type="uri">http://onlinelibrary.wiley.com/book/10.1002/9781118309421</identifier>
  <location>
    <url>http://onlinelibrary.wiley.com/book/10.1002/9781118309421</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">DLC</recordContentSource>
    <recordCreationDate encoding="marc">111222</recordCreationDate>
    <recordChangeDate encoding="iso8601">20171115133904.0</recordChangeDate>
    <recordIdentifier source="OCoLC">ocn769289644</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
